Artificial intelligence driven protein design and sustainable nanomedicine for advanced theranostics
Top Cited Papers
Open Access
- 1 June 2026
- journal article
- review article
- Published by KEAI Publishing in Bioactive Materials
- Vol. 60, 425-455
Abstract
The integration of artificial intelligence, protein engineering, and sustainable nanomedicine is driving a paradigm shift in theranostics by enabling highly precise disease diagnosis and targeted therapy. AI-driven methodologies, including machine learning and deep learning, facilitate the rapid analysis of complex biological and chemical datasets, accelerating protein structure prediction, molecular docking, and structure-activity relationship modeling. These capabilities support the rational design of proteins and peptides with enhanced specificity, therapeutic efficacy, and safety, while enabling personalized treatment strategies tailored to individual molecular profiles. In parallel, sustainable nanomedicine focuses on the development of biodegradable, biocompatible, and environmentally benign nanomaterials to improve drug bioavailability, stability, and controlled release. AI-assisted optimization further refines nanocarrier design by balancing therapeutic performance with safety and environmental impact. Advanced intelligent nanocarriers capable of real-time monitoring, adaptive drug release, and degradation into non-toxic by-products represent a significant advancement over conventional static systems. The theranostic paradigm has become central to precision medicine, particularly in oncology, especially where AI-designed nanoplatforms enable targeted delivery of imaging agents and therapeutics to tumors, while allowing continuous treatment monitoring and minimizing off-target effects. Emerging applications in neurological, infectious, and cardiovascular diseases further highlight the broad clinical potential of this approach. Accordingly, this review summarizes AI-driven protein design strategies, sustainable nanocarrier engineering, and their convergence in next-generation theranostic systems, critically discussing mechanistic insights, translational challenges, and design principles required for developing safe, scalable, and clinically adaptable intelligent nanomedicines.Keywords
Funding Information
- Wenzhou Medical University
This publication has 318 references indexed in Scilit:
- Artificial Intelligence‐Driven Nanoarchitectonics for Smart Targeted Drug DeliveryAdvanced Materials, 2025
- Applications of Artificial Intelligence in Biotech Drug Discovery and Product DevelopmentMedcomm, 2025
- ProT‐Diff: A Modularized and Efficient Strategy for De Novo Generation of Antimicrobial Peptide Sequences by Integrating Protein Language and Diffusion ModelsAdvanced Science, 2024
- Structure‐based computational design of antibody mimetics: challenges and perspectivesFEBS Open Bio, 2024
- The Role of AI in Drug DiscoveryChemBioChem, 2024
- Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in OncologyClinical Pharmacology & Therapeutics, 2024
- DPAM: A domain parser for AlphaFold modelsProtein Science, 2023
- Computational Biomaterials: Computational Simulations for BiomedicineAdvanced Materials, 2022
- BenchmarkingAlphaFoldfor protein complex modeling reveals accuracy determinantsProtein Science, 2022
- Probing Transient DNA Conformation Changes with an Intercalative Fluorescent ExcimerAngewandte Chemie, 2020